DOD Biotech Valuation
| DOD Stock | 1.95 0.01 0.51% |
Based on Macroaxis valuation methodology, the firm appears to be overvalued. DOD Biotech Public shows a prevailing Real Value of USD1.7 per share. The current price of the firm is USD1.95. Our model computes the value of DOD Biotech Public from analyzing the firm fundamentals such as Current Valuation of 2.04 B, profit margin of (0.01) %, and Shares Outstanding of 410 M as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that DOD Biotech's price fluctuation is risky at this time. Calculation of the real value of DOD Biotech Public is based on 3 months time horizon. Increasing DOD Biotech's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
DOD Biotech's intrinsic value may or may not be the same as its current market price of 1.95, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.95 | Real 1.7 | Hype 1.95 |
The intrinsic value of DOD Biotech's stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence DOD Biotech's stock price.
Estimating the potential upside or downside of DOD Biotech Public helps investors to forecast how DOD stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of DOD Biotech more accurately as focusing exclusively on DOD Biotech's fundamentals will not take into account other important factors: DOD Biotech Total Value Analysis
DOD Biotech Public is currently forecasted to have takeover price of 2.04 B with market capitalization of 2.17 B, debt of 19.31 M, and cash on hands of . Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the DOD Biotech fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
2.04 B | 2.17 B | 19.31 M |
DOD Biotech Investor Information
About 48.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.47. Some equities with similar Price to Book (P/B) outperform the market in the long run. DOD Biotech Public last dividend was issued on the 13th of March 2020. DOD Biotech Public is not in a good financial situation at the moment. It has a very high risk of going through financial straits in January.DOD Biotech Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. DOD Biotech has an asset utilization ratio of 62.4 percent. This suggests that the Company is making USD0.62 for each dollar of assets. An increasing asset utilization means that DOD Biotech Public is more efficient with each dollar of assets it utilizes for everyday operations.DOD Biotech Ownership Allocation
DOD Biotech holds a total of 410 Million outstanding shares. DOD Biotech Public retains considerable amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.DOD Biotech Profitability Analysis
The company reported the revenue of 1.02 B. Net Income was 49.79 M with profit before overhead, payroll, taxes, and interest of 437.65 M.About DOD Biotech Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of DOD Biotech Public. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of DOD Biotech Public based exclusively on its fundamental and basic technical indicators. By analyzing DOD Biotech's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of DOD Biotech's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of DOD Biotech. We calculate exposure to DOD Biotech's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of DOD Biotech's related companies.8 Steps to conduct DOD Biotech's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates DOD Biotech's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct DOD Biotech's valuation analysis, follow these 8 steps:- Gather financial information: Obtain DOD Biotech's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine DOD Biotech's revenue streams: Identify DOD Biotech's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research DOD Biotech's industry and market trends, including the size of the market, growth rate, and competition.
- Establish DOD Biotech's growth potential: Evaluate DOD Biotech's management, business model, and growth potential.
- Determine DOD Biotech's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate DOD Biotech's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Other Information on Investing in DOD Stock
DOD Biotech financial ratios help investors to determine whether DOD Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in DOD with respect to the benefits of owning DOD Biotech security.